• Veerasathpurush Allareddy, Veerajalandhar Allareddy, Natalia Martinez-Schlurmann, Sankeerth Rampa, R P Nalliah, K B Lidsky, A T Rotta, and Satheesh Elangovan.
• *Department of Orthodontics, College of Dentistry, The University of Iowa, Iowa City, IA †Division of Pediatric Critical Care, Rainbow Babies and Children's Hospital, University Hospitals, Case Medical Center, Cleveland, OH ‡Graduate student, University of Nebraska Medical Center, Omaha, NE §Office of Global Health, Harvard School of Dental Medicine, Boston, MA ¶Department of Periodontics, College of Dentistry, The University of Iowa, Iowa City, IA.
• Spine. 2015 Nov 1;40(21):1719-26.

Study DesignRetrospective study of Nationwide Inpatient Sample (NIS).ObjectiveThe objective of this study is to estimate the prevalence of complications in children who had insertion of recombinant human bone morphogenetic protein (rhBMP) at the time of spinal fusion procedures (SFP) and to examine if the use of rhBMP is associated with an increased risk of complications.Summary Of Background DataUse of rhBMP for SFP has been associated with conflicting safety profile reports in adults.MethodsNIS (years 2004-2010) was used. All patients with age  < 18 years who had a SFP during hospitalization with or without insertion of rhBMP were selected. Complications were selected based on a literature review of studies examining outcomes of SFP. Association between insertion of rhBMP and occurrence of complications was examined by multivariable logistic regression models.ResultsOf the 72,898 children who underwent SFP, 7.1% children had insertion of rhBMP. Overall complication rate was 14.34% (15.2% in rhBMP group and 14.3% in no-rhBMP group). There was no statistically significant difference in the overall complication rate [odds ratio (OR) = 1.08, 95% confidence intervals (CI) = 0.89-1.30] or among 14 different complications between rhBMP and no-rhBMP groups. Children who had rhBMP were associated with higher odds for "other infections" (OR = 2.09, 95% CI = 1.26-3.48, P = 0.004) when compared with their counterparts.ConclusionDespite the lack of Food and Drug Administration approval, rhBMP was not infrequently used in pediatric SFP. In this large retrospective study using administrative data, the use of rhBMP in children during SFP was not associated with higher risks for majority of assessed complications with the exception of "other infections". Future studies must examine the long-term impact of use of rhBMP in children with SFP.Level Of Evidence3.

23 keywords...

hide…